ReviewClinical reviews in allergy & immunology2017
The Cutaneous Spectrum of Lupus Erythematosus.
Review in Clinical reviews in allergy & immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 115 citations in OpenAlex.
- Systematic Review: Monoclonal Antibody-Induced Subacute Cutaneous Lupus Erythematosus.Drugs in R&D · 2020Pooled it
- Non-specific cutaneous lupus erythematosus and clinical significance: a literature review.Journal of rheumatic diseases · 2026Review
- Recognizing ophiasis pattern in discoid lupus: a rare diagnostic challenge.Dermatology reports · 2026Article
- Spatial characterization of skin lesions in discoid and systemic lupus erythematosus.Nature communications · 2026Article
- Epidermal Interferon-κ Drives Cutaneous Lupus-Like Lesions, Photosensitivity, and Systemic Autoimmunity In Vivo.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Chilblains With Tumid Lupus Features in a Patient With Sjögren's Syndrome: A Case Report.Cureus · 2025Article
- The role of B cell-activating factor system in autoimmune diseases: mechanisms, disease implications, and therapeutic advances.Frontiers in immunology · 2025Review
- Clinical characteristics of initial dermatomyositis presentations to the academic dermatologist.Archives of dermatological research · 2024Article
- Biomarkers for systemic lupus erythematosus: A scoping review.Immunity, inflammation and disease · 2024Article
- Morbihan Disease: A Rare Case of Periorbital Bilateral Edema with Histopathological Findings of Chronic Inflammation and Demodex Localization.The American journal of case reports · 2024Article
- Association of the Spectrum of Cutaneous Lupus Erythematosus with Disease Activity and Systemic Manifestations in Patients with Systemic Lupus Erythematosus.Mediterranean journal of rheumatology · 2024Article
- Papulonodular mucinosis with features of discoid lupus erythematosus.JAAD case reports · 2024Article
- Immune checkpoint inhibitor-induced subacute cutaneous lupus erythematosus: a case report and review of the literature.Frontiers in medicine · 2024Article
- The differential panorama of clinical features of lupus erythematosus patients with different onset ages: a cross-sectional multicenter study from China.Clinical rheumatology · 2023Article
- Review
- Lupus Nephritis and Dysbiosis.Biomedicines · 2023Review
- Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin.American journal of clinical dermatology · 2023Review
- Article
- New insight into the role of fibroblasts in the epithelial immune microenvironment in the single-cell era.Frontiers in immunology · 2023Review
- Recent advances in systemic lupus erythematosus and microbiota: from bench to bedside.Frontiers of medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus is a complex autoimmune disease with a wide spectrum of clinical and immunopathological features. Cutaneous and articular manifestations are the most common signs in patients with systemic lupus erythematosus. We here review the pathogenesis and the new classification of cutaneous lupus erythemathosus with a discussion of the significance of the various cutaneous signs. The lesions are classified according to the level of the cellular infiltrate and tissue damage in the epidermis, dermis, and/or subcutis. Furthermore, cutaneous lesions pointing to the presence of a thrombotic vasculopathy and those due to a distinct inflammatory, neutrophilic-mediated reaction pattern are highlighted. Particular attention will be given in describing the histology of skin manifestation. Treatment options for cutaneous lupus erythemathosus have increased with the introduction of new biological therapies. However, the majority of the patients still benefit from antimalarials, which remain the cornerstone of treatment. The evaluation and management of cutaneous lupus erythemathosus patients depend on the clinical findings and associated symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.